


FORM PTO 1449 (modified)				ATTY DOCKET NO. 01997.033600.4		APPLICATION NO. 09/714,792	
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)				APPLICANT Mary Collins et al.			
SEP 13 2004 				FILING DATE November 16, 2000		GROUP 1647	
U. S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLASS
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Husain, et al., "Interleukin-13 Receptor as a Unique Target for Anti-Glioblastoma Therapy", <i>Int. J. Cancer</i>, Vol. 92 (2001), pages 168-175					
FH		Barth, "hIL-13 PE38QQR NeoPharm", <i>Current Opinion in Investigational Drugs</i>, Vol. 2, No. 9 (2001), pages 1309-1313					
FH		Li, et al., "Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein <i>in vitro</i> and <i>in vivo</i> in nude mice", <i>Protein Engineering</i>, Vol. 15, No. 5 (2002), pages 419-427					
FH		Husain, et al., "Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside", <i>Journal of Neuro-Oncology</i>, Vol. 65 (2003), pages 37-48					
FH		Mintz, et al., "Molecular targeting with recombinant cytotoxins of interleukin-13 receptor $\alpha 2$-expressing glioma", <i>Journal of Neuro-Oncology</i>, Vol. 64 (2003), pages 117-123					
EXAMINER <i>Frank H. Ward</i>				DATE CONSIDERED <i>11/30/04</i>			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1